Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension
In this 24-week study, spirapril antihypertensive effect and organo-protection was assessed inpatients with metabolic syndrome (MS) and arterial hypertension (AH). Parameters of 24-hour blood pressure (BP) monitoring (systolic and diastolic BP - 24 hours, daytime, nighttime) and pulse BP were signif...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2007-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839577076250705920 |
|---|---|
| author | V. E. Oleynikov A. S. Gerasimova I. B. Matrosova Yu. A. Tomashevskaya |
| author_facet | V. E. Oleynikov A. S. Gerasimova I. B. Matrosova Yu. A. Tomashevskaya |
| author_sort | V. E. Oleynikov |
| collection | DOAJ |
| description | In this 24-week study, spirapril antihypertensive effect and organo-protection was assessed inpatients with metabolic syndrome (MS) and arterial hypertension (AH). Parameters of 24-hour blood pressure (BP) monitoring (systolic and diastolic BP - 24 hours, daytime, nighttime) and pulse BP were significantly higher in MS patients than in AH individuals. Seventy-five per cent of MS patients had pathological circadian BP profile, with non-dippers' prevalence. In the same group, more advanced target organ pathology was observed (left ventricular hypertrophy, increased vascular stiffness, microalbuminuria). Spirapril therapy was associated with target BP level achievement, circadian BP profile normalization, target organ pathology regression, and was potentially linked to insulin resistance reduction. Therefore, spirapril can be recommended for MS treatment, as well as for preventing target organ damage in MS and AH. |
| format | Article |
| id | doaj-art-3aaf7f59d6e74bf39e787727c3f4bfd6 |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2007-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-3aaf7f59d6e74bf39e787727c3f4bfd62025-08-04T13:00:01Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202007-08-010437431936Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertensionV. E. Oleynikov0A. S. Gerasimova1I. B. Matrosova2Yu. A. Tomashevskaya3Пензенский медицинский институт при ПГУПензенский медицинский институт при ПГУПензенский медицинский институт при ПГУПензенский медицинский институт при ПГУIn this 24-week study, spirapril antihypertensive effect and organo-protection was assessed inpatients with metabolic syndrome (MS) and arterial hypertension (AH). Parameters of 24-hour blood pressure (BP) monitoring (systolic and diastolic BP - 24 hours, daytime, nighttime) and pulse BP were significantly higher in MS patients than in AH individuals. Seventy-five per cent of MS patients had pathological circadian BP profile, with non-dippers' prevalence. In the same group, more advanced target organ pathology was observed (left ventricular hypertrophy, increased vascular stiffness, microalbuminuria). Spirapril therapy was associated with target BP level achievement, circadian BP profile normalization, target organ pathology regression, and was potentially linked to insulin resistance reduction. Therefore, spirapril can be recommended for MS treatment, as well as for preventing target organ damage in MS and AH.https://russjcardiol.elpub.ru/jour/article/view/2184arterial hypertensionmetabolic syndromeinsulin resistancetarget organ damagespirapril |
| spellingShingle | V. E. Oleynikov A. S. Gerasimova I. B. Matrosova Yu. A. Tomashevskaya Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension Российский кардиологический журнал arterial hypertension metabolic syndrome insulin resistance target organ damage spirapril |
| title | Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension |
| title_full | Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension |
| title_fullStr | Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension |
| title_full_unstemmed | Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension |
| title_short | Spirapril effectiveness and organo-protection in patients with metabolic syndrome and arterial hypertension |
| title_sort | spirapril effectiveness and organo protection in patients with metabolic syndrome and arterial hypertension |
| topic | arterial hypertension metabolic syndrome insulin resistance target organ damage spirapril |
| url | https://russjcardiol.elpub.ru/jour/article/view/2184 |
| work_keys_str_mv | AT veoleynikov spiraprileffectivenessandorganoprotectioninpatientswithmetabolicsyndromeandarterialhypertension AT asgerasimova spiraprileffectivenessandorganoprotectioninpatientswithmetabolicsyndromeandarterialhypertension AT ibmatrosova spiraprileffectivenessandorganoprotectioninpatientswithmetabolicsyndromeandarterialhypertension AT yuatomashevskaya spiraprileffectivenessandorganoprotectioninpatientswithmetabolicsyndromeandarterialhypertension |